TY - JOUR
T1 - Hypertrofisk kardiomyopati
T2 - Genetik, patogenese, patofysiologi, klinisk billede og forløb
AU - Bundgaard, Henning
AU - Havndrup, Ole
AU - Høst, Ulla
AU - Kelbæk, Henning S.
PY - 1998/9/14
Y1 - 1998/9/14
N2 - Hypertrophic cardiomyopathy is a heterogeneous, progressive disease with a variable age of debut Hypertrophic cardiomyopathy is characterized by myocardial hypertrophy with a bizarre fibre disarray. Angina pectoris, dyspnoea and syncope are the most frequent symptoms. Hypertrophic cardiomyopathy is an important cause of sudden death, especially in children and young adults. The aetiology is genetic in more than 60% of the cases, with an autosomal dominant mode of inheritance. More than 50 different mutations involving six genes have so far been associated with the development of hypertrophic cardiomyopathy. These mutations are located to genes coding for several of the proteins in the cardiac sarcomere. The protein changes seem to compromise contractility as well as sarcomere assembly, thereby secondarily causing compensatory hypertrophy. The management of hypertrophie cardiomyopathy has been markedly improved within the last few years. This emphasizes the importance of determining prognostic markers in each patient. A specific genetic diagnosis may prove to be of major importance.
AB - Hypertrophic cardiomyopathy is a heterogeneous, progressive disease with a variable age of debut Hypertrophic cardiomyopathy is characterized by myocardial hypertrophy with a bizarre fibre disarray. Angina pectoris, dyspnoea and syncope are the most frequent symptoms. Hypertrophic cardiomyopathy is an important cause of sudden death, especially in children and young adults. The aetiology is genetic in more than 60% of the cases, with an autosomal dominant mode of inheritance. More than 50 different mutations involving six genes have so far been associated with the development of hypertrophic cardiomyopathy. These mutations are located to genes coding for several of the proteins in the cardiac sarcomere. The protein changes seem to compromise contractility as well as sarcomere assembly, thereby secondarily causing compensatory hypertrophy. The management of hypertrophie cardiomyopathy has been markedly improved within the last few years. This emphasizes the importance of determining prognostic markers in each patient. A specific genetic diagnosis may prove to be of major importance.
UR - http://www.scopus.com/inward/record.url?scp=0032516960&partnerID=8YFLogxK
M3 - Artikel
C2 - 9763919
AN - SCOPUS:0032516960
SN - 0041-5782
VL - 160
SP - 5478
EP - 5483
JO - Ugeskrift for laeger
JF - Ugeskrift for laeger
IS - 38
ER -